EUVIMEDEUVIMED entdecken
Open Access

Retrospective analysis of Claudin18.2 expression in ethnically diverse patients with gastroesophageal adenocarcinoma

Sara Wallam iD, Jimyung Park iD, Lawrence W Wu iD, Ryan H Moy iD

Journal of Gastrointestinal Oncology · 2025-08 · 16 (4) · 1420-1433

DOI: 10.21037/jgo-2025-111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastrointestinal Oncology, 2025-08. Verfasst von Sara Wallam und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NY, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Claudin18.2 (CLDN18.2), a tight junction molecule, is a novel therapeutic target for patients with advanced gastroesophageal adenocarcinoma. Recent phase III trials demonstrated improved survival with the addition of an anti-CLDN18.2 antibody (zolbetuximab) to first-line chemotherapy. However, expression of CLDN18.2 and its association with other biomarkers, especially in racial and ethnic minorities, remains poorly defined. We evaluated CLDN18.2 expression, its association with demographic and clinicopathologic characteristics, and its prognostic potential in a cohort of ethnically diverse patients.

Methods

We conducted a single-center retrospective cohort study among patients with gastric, gastroesophageal, and esophageal adenocarcinoma in whom CLDN18.2 immunohistochemistry had been performed. Positivity was defined as moderate-to-strong expression in ≥75% of tumor cells. We extracted demographic and clinicopathologic data from the electronic medical record. Associations with CLDN18.2 were investigated using the t-test and Chi-squared test. Survival curves were calculated using the Kaplan-Meier method and compared using the log-rank test.

Results

Among 75 evaluable patients, 32 (42.7%) were CLDN18.2 positive. Mean age was 66.2 years [standard deviation (SD), 13.2 years], 34.7% were female, and 62.7%, 18.7%, and 18.7%, had primary gastric, gastroesophageal junction, and esophageal tumors, respectively. At diagnosis, 32% were metastatic. The cohort was 49.3% White, 12% Black, 8% Asian, 21.3% other, and 9.3% unknown, and 20% identified as Hispanic. By ethnicity, 53.3% of Hispanic patients were CLDN18.2 positive compared to 38.2% of non-Hispanic patients. By race, 37.8% of White, 44.4% of Black, and 50% of Asian patients were CLDN18.2 positive. In univariate analyses, CLDN18.2 positivity was significantly associated with female sex (P=0.002) and human epidermal growth factor receptor 2 (HER2) negativity (P=0.03). TP53 mutations were found in 65.2% of patients with available next-generation sequencing data, but there was no association with CLDN18.2 positivity. CLDN18.2 positivity was also not associated with disease-free survival in patients with localized or locally advanced disease, progression-free survival on first-line therapy in metastatic patients, or overall survival in the total population.

Conclusions

This study provides new information on CLDN18.2 expression in an ethnically diverse population and suggests that Hispanic patients may have higher rates of CLDN18.2 positivity than non-Hispanic patients. We also demonstrate the association between CLDN18.2 and female sex and HER2 negativity and lack of association with survival, consistent with published data. Future research should further investigate differences in CLDN18.2 expression and identify subpopulations of patients who may benefit from CLDN18.2-targeted therapies.

Schlagwörter

Stichwörter der Autor:innen

Claudin18.2 (CLDN18.2)gastric adenocarcinomahispanic ethnicity

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NY, USA.
  • Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.

ORCID-Profile: Sara Wallam, Jimyung Park, Lawrence W Wu, Ryan H Moy

Förderung

  • NCI NIH HHS

Zitieren

APA

Wallam, S., Park, J., Wu, L. W., & Moy, R. H. (2025). Retrospective analysis of Claudin18.2 expression in ethnically diverse patients with gastroesophageal adenocarcinoma. Journal of Gastrointestinal Oncology, 16(4), 1420-1433. https://doi.org/10.21037/jgo-2025-111

Vancouver

Wallam S, Park J, Wu LW, Moy RH. Retrospective analysis of Claudin18.2 expression in ethnically diverse patients with gastroesophageal adenocarcinoma. Journal of Gastrointestinal Oncology. 2025;16(4):1420-1433. doi:10.21037/jgo-2025-111

BibTeX
@article{Wallam2025,
  author = {Wallam, Sara and Park, Jimyung and Wu, Lawrence W and Moy, Ryan H},
  title = {Retrospective analysis of Claudin18.2 expression in ethnically diverse patients with gastroesophageal adenocarcinoma},
  journal = {Journal of Gastrointestinal Oncology},
  year = {2025},
  volume = {16},
  number = {4},
  pages = {1420--1433},
  doi = {10.21037/jgo-2025-111}
}
Kostenlos starten →